A new tool for detection of type I interferon activation in systemic lupus erythematosus.
The IFN-I pathway is activated in systemic lupus erythematosus (SLE) and appears to be important in the pathogenesis of the disease. As a result, several clinical trials of anti-IFN monoclonal antibodies, which hold promise to control the disease, have been launched. Additionally, activation of IFN-I might be important in the prognosis and activity assessment of the disease. Therefore, new biomarkers that reflect activity of the IFN-I pathway and are simple to measure, such as the monocyte CD64 receptor, are expected to have a great impact on the management of SLE, if properly validated.
Kirou
Kyriakos A
KA
Kalliolias
George D
GD
D015415:Biomarkers / Q000378:metabolism*; D006801:Humans; D007370:Interferon Type I / Q000276:immunology* / Q000378:metabolism*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000378:metabolism*; D011379:Prognosis
D015415:Biomarkers; D007370:Interferon Type I
Arthritis Res Ther. 2010;12(3):R90
20478071
Arthritis Rheum. 2008 Apr;58(4):1136-45
18383365
PLoS One. 2008 Apr 16;3(4):e1967
18414664
Expert Rev Clin Immunol. 2007 Jul;3(4):579-88
20477162
J Immunol. 1992 Dec 15;149(12):4048-52
1460289
Lupus. 2009 Oct;18(11):980-9
19762399
Ann Rheum Dis. 2009 Sep;68(9):1440-6
18772188
Arthritis Rheum. 2009 Oct;60(10):3098-107
19790071
Arthritis Res Ther. 2010;12 Suppl 1:S1
20392288
Immunity. 2008 Jul 18;29(1):150-64
18631455
Arthritis Rheum. 2005 May;52(5):1491-503
15880830